Effects of L-citrulline Supplementation on Vascular Function in Metabolic Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06025357 |
Recruitment Status :
Recruiting
First Posted : September 6, 2023
Last Update Posted : September 6, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metabolic Syndrome Menopause | Dietary Supplement: L-Citrulline supplementation Dietary Supplement: Placebo | Not Applicable |
Using a double-blind, randomized, placebo-controlled, and parallel design, middle-aged and older women with metabolic syndrome will be randomized into receiving either CIT supplementation (10g/day) or placebo (Microcrystalline Cellulose) for 4 weeks.
The first visit will be approximately 1hr and 30 minutes. The 2nd and 3rd visits will each be approximately 2hrs and 30 minutes, separated by 4 weeks in between each visit. During visits 2 and 3, vascular measurements will be assessed in the fasted state and 30, 60, and 90 minutes after acute glucose ingestion (75g).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Parallel Assignment Double (Participant, Investigator) Randomized, double-blind, placebo-controlled, parallel study design |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Basic Science |
Official Title: | Effects of L-Citrulline Supplementation on Vascular Function During Fasted and Acute Hyperglycemia in Middle-aged and Older Women With Metabolic Syndrome |
Actual Study Start Date : | January 1, 2023 |
Estimated Primary Completion Date : | May 1, 2024 |
Estimated Study Completion Date : | August 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: L-citrulline
L-citrulline: 10 grams/day
|
Dietary Supplement: L-Citrulline supplementation
4 weeks of L-Citrulline supplementation (10 grams/day). |
Experimental: Placebo
Microcrystalline Cellulose
|
Dietary Supplement: Placebo
4 weeks of microcrystalline Cellulose supplementation. |
- Macrovascular Endothelial function in the fasted condition [ Time Frame: 4 weeks ]Endothelial function will be measured via brachial artery flow mediated dilation (ultrasonography) during reactive hyperemia at baseline and after 4 weeks of supplementation.
- Microvascular endothelial function in the fasted condition [ Time Frame: 4 weeks ]Endothelial function will be measured using forearm muscle oxygenation (near-infrared spectroscopy) will assessed during reactive hyperemia at baseline and after 4 weeks of supplementation.
- Microvascular digital endothelial function in the fasted condition [ Time Frame: 4 weeks ]Endothelial function will be measured using peripheral (finger) arterial tonometry (EndoPAT device) during reactive hyperemia at baseline and after 4 weeks of supplementation.
- Macrovascular Endothelial function during acute hyperglycemia [ Time Frame: 4 weeks ]Endothelial function will be measured via brachial artery flow mediated dilation (ultrasonography) during reactive hyperemia at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
- Microvascular forearm endothelial function during acute hyperglycemia [ Time Frame: 4 weeks ]Endothelial function will be measured using forearm muscle oxygenation (near-infrared spectroscopy) during reactive hyperemia at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
- Central and peripheral arterial stiffness in the fasted condition [ Time Frame: 4 weeks ]Arterial stiffness will be measured using central (carotid-femoral) and peripheral (femoral-ankle) PWV at baseline and after 4 weeks of supplementation.
- Central arterial stiffness during acute hyperglycemia [ Time Frame: 4 weeks ]Arterial stiffness will be measured using central (carotid-femoral) PWV at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
- Blood pressure in the fasted condition [ Time Frame: 4 weeks ]Brachial and aortic blood pressures will be assessed using an automated sphygmomanometry arm cuff (SphygmoCor XCEL). Beat-to-beat blood pressure will be measured using an automated photoplethysmography finger cuff (Fineometer). Blood pressure will be measured at baseline and after 4 weeks of supplementation.
- Blood pressure during acute hyperglycemia [ Time Frame: 4 weeks ]Brachial and aortic blood pressures (systolic and diastolic) will be assessed using an automated sphygmomanometry arm cuff (SphygmoCor XCEL). Beat-to-beat blood pressure will be measured using an automated photoplethysmography finger cuff (Fineometer). Blood pressure will be measured after an oral glucose ingestion at 30, 60, and 90 minutes at baseline and after 4 weeks of supplementation.
- Total peripheral resistance in the fasted condition. [ Time Frame: 4 weeks ]Total peripheral resistance will be measured using an automated photoplethysmography finger cuff (Finometer) at baseline and after 4 weeks of supplementation.
- Total peripheral resistance during acute hyperglycemia [ Time Frame: 4 weeks ]Total peripheral resistance will be measured using an automated photoplethysmography finger cuff (Finometer) at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
- Stroke volume in the fasted condition [ Time Frame: 4 weeks ]Stroke volume will be measured using an automated photoplethysmography finger cuff (Finometer) at baseline and after 4 weeks of supplementation.
- Stroke volume during acute hyperglycemia [ Time Frame: 4 weeks ]Stroke volume will be measured using an automated photoplethysmography finger cuff (Finometer) at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
- 24-hour ambulatory blood pressure monitoring [ Time Frame: 4 weeks ]An ambulatory blood pressure cuff, measuring blood pressure for 24-hours will be obtained on two separate days at baseline and after 4 weeks of supplementation.
- Serum glucose and insulin levels. [ Time Frame: 4 weeks ]Serum glucose and insulin levels will be tested at baseline and after 4 weeks of supplementation.
- Serum arginine levels [ Time Frame: 4 weeks ]Serum L-Arginine levels will be tested at baseline and after 4 weeks of supplementation.
- Serum arginase levels [ Time Frame: 4 weeks ]Serum arginase levels will be tested at baseline and after 4 weeks of supplementation.
- Serum Nitric Oxide levels [ Time Frame: 4 weeks ]Serum nitric oxide levels will be tested at baseline and after 4 weeks of supplementation.
- Serum Endothelin-1 levels [ Time Frame: 4 weeks ]Serum endothelin-1 levels will be tested at baseline and after 4 weeks of supplementation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 79 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Must present at least 3 of the following 5 cardiometabolic risk factors
- Waist circumference ≥88 cm
- Fasting glucose between 100-125 mg/dL or HbA1c between 5.7-6.4%.
- Blood pressure ≥130 mm Hg
- Triglyceride ≥ 150 mg/dL
- HDL <50 mg/dL
The following are also inclusion criteria's:
- Women aged 45-79 years old
- Body mass index ≤ 39.9 kg/m2
- Sedentary (defined as < 120 min/week of exercise)
- Abstain from any dietary supplements with vascular effects for one month prior to the beginning of the study and until participation in study has terminated.
Exclusion Criteria:
- < 45 and > 79 years of age
- Use of medications and/or any supplements that may affect outcome variables (such as arginine-containing supplements, nitroglycerin, statin drugs, biguanides, insulin, beta blockers, statins, verapamil)
- Systolic blood pressure ≥ 160 mmHg
- BMI > 40 kg/m2
- Recent changes in medication (3 months)
- Current smoking any tobacco use
- Cardiovascular disease, diabetes (Type 1 or 2), and other metabolic or chronic diseases
- More than 7 alcoholic drinks/week of consumption
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06025357
Contact: Arturo Figueroa, Ph.D,MD | 806-834-5587 | arturo.figueroa@ttu.edu |
United States, Texas | |
TTU Kinesiology and Sport Management Building | Recruiting |
Lubbock, Texas, United States, 79409 | |
Contact: Arturo Figueroa, M.D., Ph.D. 806-834-5587 |
Principal Investigator: | Arturo Figueroa | Texas Tech University |
Other Publications:
Responsible Party: | Arturo Figueroa, Arturo Figueroa, Principal Investigator, Texas Tech University |
ClinicalTrials.gov Identifier: | NCT06025357 |
Other Study ID Numbers: |
IRB2022-362 |
First Posted: | September 6, 2023 Key Record Dates |
Last Update Posted: | September 6, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Endothelial function Aortic Hemodynamics Blood pressure Obesity Hypertension |
Metabolic Syndrome Syndrome Disease Pathologic Processes |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |